ArticleCureus2025
A Rare Case of Primary Cutaneous Epstein-Barr Virus-Positive T Follicular Helper Cell Lymphoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We herein report a case of Epstein-Barr virus-positive primary cutaneous T follicular helper cell lymphoma (EBV-positive pcTFHL) in an elderly patient. The patient presented with multiple erythemas and cutaneous and subcutaneous nodules on the legs without internal organ involvement. Histology demonstrated diffuse infiltrates of atypical small- to medium-sized lymphoid cells in the dermis and subcutis associated with exocytosis in the epidermis and extensive necrosis in the deep dermis. Immunohistochemistry demonstrated that the atypical lymphoid cells were CD3- and CD4-positive T cells and expressed TFH cell markers. The CD4-positive atypical lymphoid cells were also diffusely positive for EBV byin situ hybridization, confirming the diagnosis of EBV-positive pcTFHL. The clinical course was progressive: large multiple cutaneous ulcers developed, and the patient died of fibrinous and organizing pneumonia due to COVID-19. The total clinical course was two years and two months after the onset of the skin rashes. This is the third case of EBV-positive pcTFHL that showed EBV infection exclusively in CD3- and CD4-positive T cells and had a lethal progressive clinical course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.